Company intelligence / Profile preview
CytoMed Therapeutics
Singapore, Singaporecytomed.sg ↗
- Ownership
- Public · GDTC
- Employees
- ~28
- Development stage
- Phase 1
01
Overview
CytoMed’s lead program CTM-N2D has entered Phase I clinical trials for cancer. Other programs are in preclinical development targeting both oncology and regenerative medicine. The company leverages proprietary platforms for off-the-shelf allogeneic cellular therapies using gamma delta T cells, NKTs, and mesenchymal stem cells[1][3].
- Therapeutic areas
- OncologyRheumatology
- Modalities
- Cell-based immunotherapies (gamma delta T cells, natural killer (NK) cells)Induced pluripotent stem cell (iPSC)-derived therapeuticsMesenchymal stem cells
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Sengkang General Hospital (Singapore): research collaboration on CTM-MSC for in vivo studies and clinical trial[3]SunAct Cancer Institute Private Limited (India): advancing use of allogeneic off-the-shelf Gamma Delta T Cells for solid cancers[3]
04
Financials
- Market cap
- $9.6M
- Total revenue
- $167.9K
- Enterprise value
- $8M
Beyond the preview
Go deeper on CytoMed Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoMed Therapeutics.